Need Assistance?

US & Canada:
+
UK: +

Our Highlights

GMP Grade Efficient workshop for GMP production.
Optimal Prices Buying products on this site guarantees the best price!
Commercial Batches Independent GMP manufacturing suites that handle commercial batches
Prompt Delivery Warehouses in multiple cities to ensure timely delivery
Flexible Quantity Quantities available from milligrams to ton

N-Acetylcysteine Amide

* Please kindly note that our products are not to be used for therapeutic purposes and cannot be sold to patients.

N-Acetylcysteine amide is a blood brain barrier permeant and cell membranes thiol antioxidant with anti-inflamatory activity via regulation of activation of NF-κB and HIF-1α as well as modulation of ROS. It readily crosses cell membranes, replenishes intracellular GSH, and defends the cell from oxidative stress. It may be used in research and exploration for the treatment of radiation exposure, neurodegeneration and other oxidation-mediated disorders. It is also used for the treatment of acquired immune deficiency syndrome and HIV infection. It is also used as an authentic imaging probe for accurate tracing of cells viability from beginning to end to distinguish apoptotic and necrotic cells. It improves neuronal mitochondrial bioenergetics, reduces tissue damage and enhances behavioral recovery in rats following traumatic brain injury. It is a neuroprotective agent.

Category

Other Unnatural Amino Acids

Catalog number

BAT-008155

CAS number

38520-57-9

Molecular Formula

C5H10N2O2S

Molecular Weight

162.21

Size	Price	Stock	Quantity
1 g	$439	In stock

IUPAC Name

(2R)-2-acetamido-3-sulfanylpropanamide

Synonyms

(2R)-2-(Acetylamino)-3-mercaptopropanamide;N-Acetyl-L-cysteinamide

Appearance

white to off-white lyophilized powder

Density

1.226±0.06 g/cm3(Predicted)

Boiling Point

441.0±40.0 °C(Predicted)

Storage

Store at -20°C

InChI

InChI=1S/C5H10N2O2S/c1-3(8)7-4(2-10)5(6)9/h4,10H,2H2,1H3,(H2,6,9)(H,7,8)/t4-/m0/s1

InChI Key

UJCHIZDEQZMODR-BYPYZUCNSA-N

Canonical SMILES

CC(=O)NC(CS)C(=O)N

N-Acetylcysteine Amide is a derivative of N-Acetylcysteine with enhanced properties and multiple benefits in health and medicine. Here are some key applications of N-Acetylcysteine Amide:

Neuroprotection: N-Acetylcysteine Amide is known for its neuroprotective properties, which can help treat neurodegenerative disorders such as Alzheimer’s and Parkinson’s disease. It acts by reducing oxidative stress and inflammation in neural tissues, thereby protecting neurons from damage. Research shows that it enhances glutathione levels in the brain, a crucial antioxidant for maintaining neural health.

Pulmonary Health: This compound is used in treating lung diseases due to its mucolytic and antioxidant effects. It helps reduce mucus viscosity, improving airway clearance in conditions like chronic obstructive pulmonary disease (COPD) and cystic fibrosis. Additionally, it combats oxidative stress in lung tissues, reducing inflammation and promoting better respiratory function.

Liver Support: N-Acetylcysteine Amide shows promise in protecting and enhancing liver function, particularly in cases of liver damage or toxicity. It supports the detoxifying capacity of the liver by boosting intracellular glutathione levels, crucial for neutralizing harmful substances. This makes it a potential therapeutic agent for managing acetaminophen overdose and chronic liver diseases.

Cancer Therapy: In oncology, N-Acetylcysteine Amide is explored for its potential to augment cancer treatments by mitigating side effects. It protects normal cells from chemotherapy-induced oxidative damage, while not interfering with the therapeutic action on cancer cells. Furthermore, it is being investigated for its ability to modulate redox status in cancer cells, potentially enhancing the efficacy of certain chemotherapeutic agents.

1.N-acetylcysteine amide, a promising antidote for acetaminophen toxicity.

Khayyat A1, Tobwala S1, Hart M2, Ercal N3. Toxicol Lett. 2016 Jan 22;241:133-42. doi: 10.1016/j.toxlet.2015.11.008. Epub 2015 Nov 19.

Acetaminophen (N-acetyl-p-aminophenol, APAP) is one of the most widely used over the counter antipyretic and analgesic medications. It is safe at therapeutic doses, but its overdose can result in severe hepatotoxicity, a leading cause of drug-induced acute liver failure in the USA. Depletion of glutathione (GSH) is one of the initiating steps in APAP-induced hepatotoxicity; therefore, one strategy for restricting organ damage is to restore GSH levels by using GSH prodrugs. N-acetylcysteine (NAC), a GSH precursor, is the only currently approved antidote for an acetaminophen overdose. Unfortunately, fairly high doses and longer treatment times are required due to its poor bioavailability. In addition, oral and I.V. administration of NAC in a hospital setting are laborious and costly. Therefore, we studied the protective effects of N-acetylcysteine amide (NACA), a novel antioxidant with higher bioavailability, and compared it with NAC in APAP-induced hepatotoxicity in C57BL/6 mice.

2.Methotrexate Promotes Platelet Apoptosis via JNK-Mediated Mitochondrial Damage: Alleviation by N-Acetylcysteine and N-Acetylcysteine Amide.

Paul M1, Hemshekhar M2, Thushara RM1, Sundaram MS1, NaveenKumar SK1, Naveen S3, Devaraja S4, Somyajit K5, West R6, Basappa7, Nayaka SC8, Zakai UI6, Nagaraju G5, Rangappa KS9, Kemparaju K1, Girish KS10. PLoS One. 2015 Jun 17;10(6):e0127558. doi: 10.1371/journal.pone.0127558. eCollection 2015.

Thrombocytopenia in methotrexate (MTX)-treated cancer and rheumatoid arthritis (RA) patients connotes the interference of MTX with platelets. Hence, it seemed appealing to appraise the effect of MTX on platelets. Thereby, the mechanism of action of MTX on platelets was dissected. MTX (10 μM) induced activation of pro-apoptotic proteins Bid, Bax and Bad through JNK phosphorylation leading to ΔΨm dissipation, cytochrome c release and caspase activation, culminating in apoptosis. The use of specific inhibitor for JNK abrogates the MTX-induced activation of pro-apoptotic proteins and downstream events confirming JNK phosphorylation by MTX as a key event. We also demonstrate that platelet mitochondria as prime sources of ROS which plays a central role in MTX-induced apoptosis. Further, MTX induces oxidative stress by altering the levels of ROS and glutathione cycle. In parallel, the clinically approved thiol antioxidant N-acetylcysteine (NAC) and its derivative N-acetylcysteine amide (NACA) proficiently alleviate MTX-induced platelet apoptosis and oxidative damage.

3.N-Acetylcysteine Amide Protects Against Oxidative Stress-Induced Microparticle Release From Human Retinal Pigment Epithelial Cells.

Carver KA, Yang D. Invest Ophthalmol Vis Sci. 2016 Feb 1;57(2):360-71. doi: 10.1167/iovs.15-17117.

PURPOSE: Oxidative stress is a major factor involved in retinal pigment epithelium (RPE) apoptosis that underlies AMD. Drusen, extracellular lipid- and protein-containing deposits, are strongly associated with the development of AMD. Cell-derived microparticles (MPs) are small membrane-bound vesicles shed from cells. The purpose of this study was to determine if oxidative stress drives MP release from RPE cells, to assess whether these MPs carry membrane complement regulatory proteins (mCRPs: CD46, CD55, and CD59), and to evaluate the effects of a thiol antioxidant on oxidative stress-induced MP release.

4.Neuroprotective effects of N-acetylcysteine amide on experimental focal penetrating brain injury in rats.

Günther M1, Davidsson J2, Plantman S3, Norgren S4, Mathiesen T5, Risling M3. J Clin Neurosci. 2015 Sep;22(9):1477-83. doi: 10.1016/j.jocn.2015.03.025. Epub 2015 Jun 19.

We examined the effects of N-acetylcysteine amide (NACA) in the secondary inflammatory response following a novel method of focal penetrating traumatic brain injury (TBI) in rats. N-acetylcysteine (NAC) has limited but well-documented neuroprotective effects after experimental central nervous system ischemia and TBI, but its bioavailability is very low. We tested NACA, a modified form of NAC with higher membrane and blood-brain barrier permeability. Focal penetrating TBI was produced in male Sprague-Dawley rats randomly selected for NACA treatment (n=5) and no treatment (n=5). In addition, four animals were submitted to sham surgery. After 2 hours or 24 hours the brains were removed, fresh frozen, cut in 14 μm coronal sections and subjected to immunohistochemistry, immunofluorescence, Fluoro-Jade and terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) analyses. All treated animals were given 300 mg/kg NACA intraperitoneally (IP) 2 minutes post trauma.